Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edgar Ramirez

Interventional Pain Medicine Wesley Chapel, FL Medical Doctor

NPI 1548242399 CMS profile 24136

2818 Cypress Ridge Blvd Ste 100, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$14,895

506 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edgar Ramirez of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $14,895 across 506 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,047 96
2024 General $2,926 71
2023 General $2,925 61
2022 General $2,661 79
2021 General $1,344 80
2020 General $922 59
2019 General $1,070 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edgar Ramirez
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Edgar Ramirez were reported at $3,047. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Edgar Ramirez Interventional Pain Medicine median Middle half National median
2019 $1,070 $684 $216–$2,079 $163
2020 $922 $382 $122–$1,109 $114
2021 $1,344 $552 $167–$1,554 $132
2022 $2,661 $605 $187–$1,924 $149
2023 $2,925 $671 $195–$1,915 $160
2024 $2,926 $684 $206–$1,837 $164
2025 $3,047 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relievant Medsystems, Inc. $2,933 28 payments
  2. Boston Scientific Corporation $2,222 60 payments
  3. Spinal Simplicity, LLC $1,942 30 payments
  4. Collegium Pharmaceutical, Inc. $982 49 payments
  5. AbbVie, Inc. $735 34 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $696 47 payments
  7. Allergan Inc. $541 35 payments
  8. Pfizer Inc. $419 16 payments
  9. Saluda Medical Americas, Inc. $410 4 payments
  10. Teva Pharmaceuticals USA, Inc. $376 30 payments
  11. Other $3,638 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,511 496 payments
  2. Travel and Lodging $2,306 9 payments
  3. Education $78 1 payment
Products named General payments · program years 2019–2025
  1. Intracept Pain $2,990 30 payments
  2. HA MINUTEMAN G3-R $1,942 30 payments
  3. Intracept Pain $1,612 19 payments
  4. Intracept Pain $1,612 19 payments
  5. Intracept Pain $1,612 19 payments
  6. Intracept Pain $1,322 9 payments
  7. XTAMPZA $982 49 payments
  8. RELISTOR Gastroenterology $684 46 payments
  9. Intracept Intracept Access Instruments (Gen 3)_NMOD $579 15 payments
  10. RELISTOR Gastroenterology $546 37 payments
  11. Other $8,278 369 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

7,341

Median for Interventional Pain Management: 1,220

Drug cost

$734,283

Median for Interventional Pain Management: $39,344

Branded share of claims

42.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 456 $251,898
Nucynta Er Tapentadol Hcl Brand 52 $86,382
Belbuca Buprenorphine Hcl Brand 57 $53,661
Oxycontin Oxycodone Hcl Brand 89 $50,948
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,186 $41,388
Percocet Oxycodone Hcl/Acetaminophen Brand 12 $40,581
Relistor Methylnaltrexone Bromide Brand 11 $26,190
Buprenorphine Generic 163 $25,725
Oxycodone Hcl Generic 1,077 $19,833
Morphine Sulfate Er Morphine Sulfate Brand 415 $13,014

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$493,105

Of which drugs: $2,458

Medicare patients

298

Average age 72

Services billed

10,143

176 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 44%
Depression 37%
Diabetes 31%
Chronic kidney disease 31%
COPD 27%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 241 6,527 $578
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 116 $89

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $121
$121 456 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $85
$85 11 —
BOTOX
  • AbbVie, Inc. $66
$66 — —
QULIPTA
  • AbbVie, Inc. $50
$50 — —
UBRELVY
  • AbbVie, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

506 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record